Shares of Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM – Get Free Report) shot up 1.8% on Monday . The company traded as high as $16.78 and last traded at $16.64. 2,910 shares were traded during trading, an increase of 35% from the average session volume of 2,151 shares. The stock had previously closed at $16.35.
Amplify Treatments, Testing and Advancements ETF Price Performance
The firm has a 50 day moving average price of $17.97 and a 200-day moving average price of $17.99. The firm has a market cap of $9.15 million, a price-to-earnings ratio of 6.35 and a beta of 0.87.
Amplify Treatments, Testing and Advancements ETF Company Profile
The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.
Featured Stories
- Five stocks we like better than Amplify Treatments, Testing and Advancements ETF
- The Most Important Warren Buffett Stock for Investors: His Own
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Which Wall Street Analysts are the Most Accurate?
- Merger or Not, Albertson’s Companies is a Good Buy
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Amplify Treatments Testing and Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Treatments Testing and Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
